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ABSTRACT 
Objective: The aim of the work was to study the absolute and relative bioavailability (using rabbits) of ondansetron HCl (ONH)from our newly 
prepared intranasal mucoadhesive nanoemulsion in situ gel (NIG) in comparison to intranasal mucoadhesive in situ gel (IG) prepared by the 
conventional method and intravenous injection. 
Methods: Six male rabbits weighing 2.5-3 kg were used in this study, where the dose of ondansetron HCl (ONH) was calculated based on the body 
surface area (BSA) which is equivalent to 140μl (containing 10 mg/ml) of NIG and IG and 700μl of intravenous ZofranP® Pinjection (containing 2 
mg/ml) were given to the rabbits, separated with one week washout period. Serial blood samples were withdrawn and analyzed for simultaneous 
determination of the drug using HPLC (Knaure; 150 ×4.6 mm; 5 μm particle size; 25 cm length) supported by guard column C18-4 mm diameter. 
Results: The pharmacokinetics parameters for NIG; Cmax, Tmax, AUC0-t, AUC0-∞were found to be greater than conventional in situ gel (IG). In vivo 
pharmacokinetic studies in rabbits showed a significant increase in CRmaxR and AUC R0-αR(P<0.001) with shorter TRmax Rusing NIG compared to IG 
containing the same NIG excipients, while the absolute bioavailability for NIG and IG (was 80.541 and 51.068 respectively). 
Conclusion: The present studies ratify the bioavailability enhancement potential of NE used to prepare NIG for the drug and significantly high 
absolute bioavailability to be used as a successful alternative route to the IV injection and improve patient compliance. 
Keywords: Bioavailability study, In situ gel, Nanoemulsion, NIG, Ondansetron HCl 




Ondansetron HCl (ONH) is an antiemetic drug used as the first-line 
drug for the management of nausea and vomiting associated with 
cancer chemotherapy, chronic medical illness, gastroenteritis and 
post-operative states [1]. Oral ondansetron HCl (ONH) exhibits low 
bioavailability (i.e., 60 %) due to extensive hepatic oxidative 
metabolism (95%) to form hydroxylated metabolites, which is 
mediated through multiple cytochrome P450 forms. The myriad 
drug delivery systems of ondansetron HCl (ONH) developed so far 
have yielded limited fruition in oral bioavailability enhancement [2].  
Drugs administered through nasal route absorb rapidly and reach 
therapeutically effective plasma levels quickly due to the rich 
vasculature and highly permeable membranes in the nasal cavity [3]. 
Moreover, the nasal route offers an additional advantage over the 
oral route, particularly for those drugs that have poor oral 
bioavailability due to pH instability and enzyme degradation in the 
gastrointestinal tract (GIT). Further, drugs that undergo gut wall 
metabolism, P-glycoprotein efflux, and high hepatic first-pass 
metabolism are also benefited from nasal route of administration 
[4]. For a few drugs, plasma drug profiles from intranasal delivery 
are akin to that of intravenous drug profile of the same drug [5]. 
Recently, nanoemulsion (NE) is being seen as a carrier for intranasal 
delivery of drugs as it is more stable than other vesicular systems 
likes liposomes, ethosomes, niosomes, etc. They are translucent 
mixtures of oil, surfactant, cosurfactant, and water, in which either 
the oil globules are dispersed in water (o/w) or water globule are 
dispersed in oils (w/o). These systems are single, optically isotropic 
and thermodynamically stable with a droplet size typically in the 
range of 10-100 nm [6]. 
Due to low bioavailability of ondansetron HCl (ONH) and its inability 
to reach high concentration in plasma after oral administration, it 
was excogitated to develop a novel dosage form for ondansetron HCl 
(ONH) that could address these problems through delivery of the 
drug into intranasal route to improve its bioavailability (by 
avoidance of first-pass metabolism). 
However, owing to the anatomical and physiological conditions of 
the nasal cavity, intranasally administered drugs have low residence 
time at the site of administration. Rapid mucociliary clearance (MC) 
also limits the time available for drug absorption [4]. Therefore, in 
the design of intranasal formulations, one must address the problem 
of low residence time in the nasal cavity. Possible strategy to 
improve nasal residence time is to use formulations with higher 
viscosity, and preferably, with mucoadhesive character. Designing 
an intranasal dosage form with mucoadhesive character is 
particularly helpful because it provides intimate contact between 
dosage form and nasal epithelium thereby maximizing the chances 
of absorption for a drug molecule. Temperature sensitive in situ gel 
provide a suitable dosage form; they are easy to administer and have 
a suitable viscosity at body temperature to counter mucocilliary 
clearance (MC) [7]. 
In our previous studies; a mucoadhesive nasal in situ gel for ONH 
was prepared through the application of NE technology (NIG) where 
poloxamer 407 was used as thermo reversible polymer and chitosan 
and HPMC E15 were used as mucoadhesive polymers, NIG was 
evaluated in vitro and gave 100% release after 6 h with sharp burst 
effect. In addition, a nasal in situ gel (IG) containing the same 
contents of the nanoemulsion in situ gel(NIG) prepared by the 
conventional method and tested in vitro to show 60% release after 6 
h [8, 9]. 
This study involves the in vivo estimation (for the first time) of the 
contribution of nanoemulsion (NE) as a carrier for ondansetron HCl 
(ONH) in our newly developed mucoadhesive intranasal in situ gel 
through studying the bioavailability of the drug relative to the 
intranasal in situ gel prepared by the conventional way (without 
carrier),as well as through comparing its bioavailability from these 
preparations to intravenous injection (ZofranP® P) of the drug 
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(absolute bioavailability) to estimate its use as alternative dosage 
form than IV injection to be safe medicated and improve patient 
compliance. 
MATERIALS AND METHODS 
Materials 
Ondansetron HCl [Hangzhou Hyper chemicals, China], HPMC E15, 
poloxamer407and chitosan [H-imedia Laboratories Pvt. Ltd., 
Mumbai, India], tween 20 [J. T Baker, China], acetonitrile and 
methanol absolute-HPLC grade [Biosolve B V, France], oleic acid [Al-
Emad company, Iraq]. Tetra-methyl-butyl ether-HPLC grade [Baoji 
Guokang Biotechnology Co, Ltd. China]. For all the experiments, 
deionized distilled water (DDW) was used. 
Methodology 
Study design 
The protocol for the study was approved (approval number 
205/2017) by animal care committee in the Iraqi national center for 
drugs control and researches. Briefly, six male, white rabbits 
weighing 2.5-3 kg were caught in rabbit hutch during blood samples 
collection. The rabbits were then positioned on a table supported in 
a horizontal position. The nasal and intravenous dose of rabbits 
were calculated, an equivalent amount of ondansetron HCl (ONH) 
were administrated to the animal. The calculation of animal nasal 
and intravenous (rabbit) doses was based on the body surface area 
(BSA) normalization method and the human equivalent dose (HED) 
of pharmaceuticals involving the species (Km) factor (body weight in 
kg divided by BSA in mP2P) according to the following equation [10]: 
HED(mg) = Animal dose (mg) × (
AnimalKm
HumanKm
)  Eq. 1 
The recommended adult human single dose of ondansetron HCl 
(ONH) per day is (three 0.15 mg/kg), and the values of Km were 37 
and 12 for adult human and rabbit respectively [11]. Hence, 
ondansetron HCl (ONH) dose for rabbit based on BSA normalization 
method was 1.4 mg. A micropipette tip (100–200 μl amplitude) 
layed 1 cm deep inside the right nostril of each rabbits, was used to 
administer 140μl (containing 10 mg/ml) of selected NIG formula and 
conventional intranasal in situ gel (IG). Intravenous administration 
of 700 μl ZofranP®P injection (2 mg/ml) was given to the rabbits. Blood 
samples (2 ml) were withdrawn from the marginal ear vein at zero 
time (first minute after administration) and 0.25, 0.5, 1.0, 2.0, 3.0, 
5.5, 7.5, 10 and 24 h. Blood samples were centrifuged to collect 
plasma and collected in tubes containing EDTA and immediately 
frozen at–20 °C until analysis [12]. 
Construction of calibration curve of OND-HCl in plasma by HPLC 
A stock solution of ondansetron HCl (ONH) (1 mg/ml) was prepared 
by dissolving 10 mg of ondansetron HCl (ONH) in 10 ml methanol. 
Ondansetron HCl (ONH) working solutions were prepared by serial 
dilutions of the stock solution in methanol to obtain the final 
concentrations of (1-80 µg/ml). Calibration curves for ondansetron 
HCl (ONH) were prepared by spiking blank plasma with the working 
solutions (after evaporation of methanol) to get dilution (ten times) 
providing the definitive concentrations of (100-8000 ng/ml). The 
working plasma solutions of ondansetron HCl (ONH) were saved at 4 
°C till use. The calibration curve was constructed by plotting area 
under the peak (Y) versus ondansetron HCl (ONH) concentrations 
(X). A linear regression (rP2P) method was used for quantification [13].  
Set up of plasma samples 
A 50 μl portion of thawed rabbit plasma was presented into a glass 
tube at room temperature and 1.0 ml of methyl tetra-butyl ether 
(MTBE) as the extraction solvent. After eddy blending for 20 s, 
samples were centrifuged (3500 rpm/3 min) at 4 °C and transfer the 
organic phase to other clean glass tubes set then evaporation of the 
organic phase to get dry residues using nitrogen at 50 °C. A 500 µl of 
acetonitrile-water (50:50, v/v) was used to dissolve the dry 
residues, then eddy blending (10 s) for residue reconstitution [14]. 
The procedure was completed as mentioned under the construction 
of the calibration curve of ondansetron HCl (ONH) in plasma. 
Chromatographic conditions 
A 50 µl of extracted samples were injected into a Knauer HPLC 
system (Germany) which consist of a Wellchrom K-1001 pump, a 
Rheodyne 7125 injector and a K 2501 UV detector with a 
thermostatic column compartment connected to a Eurochrom 2000 
injector. A high-performance liquid chromatography was performed 
on an analytical C18 column (Knaure; 150×4.6 mm; 5 μm particle 
size; 25 cm length) supported by guard column C18-4 mm diameter 
(Germany). The wavelength was set at 303 nm. The mobile phase 
was acetonitrile-water (50:50, v/v) with 0.25 mmol ammonium 
formate at a flow-rate of 0.80 ml/min. Under these conditions, 
typical standard retention times were 3±0.5 min for ondansetron 
HCl (ONH). The autosampler was maintained at 4 °C and the total 
run time was 4.0 min [14, 15]. 
Pharmacokinetic parameters 
Non-compartmental pharmacokinetic analysis for ondansetron HCl 
(ONH) was performed. The maximum plasma drug concentration 
(CRmaxR) and the time required to reach maximum plasma 
concentration (TRmaxR) after intravenous and nasal administration 
were directly determined from the plasma concentration-time curve. 
Also, the elimination rate constant (Ke), derived from the slope of 
the straight part of the terminal phase (where the slope equal to–
Ke/2.303) [16], the elimination half-life time (tR1/2)R, derived from 
0.693/Ke [19], the area under the plasma concentration-time curve 
from 0-24 h (AUC R0-24R) and the area under plasma concentration-
time curve from 0-α (AUCR0-αR) were calculated for each individual 
rabbit. The AUCR0-24 Rwas calculated using trapezoidal rule and 
extrapolation of the area to infinity (AUCR0-αR) was estimated by 
adding the last measured plasma concentration divided by the 
elimination rate constant (Ke) to AUCR0-24R according to the following 
equation [17]: 
AUC0−α =  
AUC0−24 + C24
Ke
 Eq. 2  
Where; C24 is the concentration of ONH after 24 h. The absolute and 
relative bioavailability percent was calculated from the following 
equations, respectively [18]: 
% F absolute……….% F = AUCtestAUCIV  x
DoseIV
Dosetest
× 100 Eq. 3 
% F relative.……….% F = AUCIGAUCNIG  x
Dose NIG
DoseIG
× 100 Eq. 4 
Statistical analysis of bioavailability study 
Comparison between the pharmacokinetic parameters of 
ondansetron HCl (ONH) following the administration of marketed 
Zofran IV injection, prepared NIG and conventionally prepared IG 
formulations were carried out using one-way analysis of variance 
(ANOVA) followed by tukey-multiple comparison test. Statistical 
calculation was carried out using Graph Pad Prism 7.0 software. 
RESULTS AND DISCUSSION  
Bioavailability study 
The concentration of ondansetron HCl (ONH) in rabbit’s blood was 
determined using a reproducible, sensitive and rapid HPLC 
method. Fig. 1 showed peak chromatograms for ONH in standard 
solution and in a working plasma sample, the chromatographic 
conditions and extraction procedure yielded a clear chromatogram 
for analysis. 
The retention time of ondansetron HCl (ONH) was detected in 
methanol and in plasma samples and was recorded to be 3±0.5 min. 
The lower limit of detection of the drug in plasma by HPLC was 
measured by preparing different concentrations of ondansetron HCl 
(100-8000 ng/ml) in plasma and it was found to be 188.9 ng/ml.  
Fig. 2 showed the calibration curve of ondansetron HCl (ONH) in 
plasma. A straight line with high regression coefficient (rP2P= 0.9995) 
was obtained by plotting the area under the peak versus the 
concentration (in the plasma working range 100-8000 ng/ml), this 
indicates that the calibration curve obey Beer’s law within the range 
of concentration used. 
Maraie et al. 
Int J App Pharm, Vol 10, Issue 5, 2018, 105-109 
107 
 
Fig. 1: Representative HPLC chromatograms of standard solution (STD) and working plasma sample of ondansetron HCl (ONH) 
 
 
Fig. 2: Calibration curve of ondansetron HCl (ONH) in plasma by HPLC 
 
Fig. 3 depicts the mean plasma concentration profile as a function of 
time for the optimized nanoemulsion in situ gel (NIG) in comparison 
to prepared conventional in situ gel (IG) and in comparison to 
marketed IV injection (Zofran®) by using crossover design with one 
week washout period. The mean blood concentration versus time 
profile revealed that first order pharmacokinetic model without lag 
time and first-order elimination rate was considered to be the best 
fit to explain the generated data, where the drug concentration in 
plasma after administration of the dose and progressing of analysis, 
the concentration increased until reached the peak level (Cmax). After 
the peak level of the drug was reached, the plasma level of the drug 
decreased indicating that the rate of elimination from plasma stream 
is greater than the rate of absorption(absorption process does not 
terminate). 
Table 1 illustrated the arithmetic mean and standard deviation 
values of plasma drug concentration (ng/ml) of ondansetron HCl 
(ONH) at the selected time intervals for 6 rabbits having different 
weights (2.5-3 kg) and receiving single dose of ONH (1.4 mg) of the 
prepared nanoemulsion in situ gel (NIG), conventional prepared in 
situ gel (IG) and commercial Zofran® injection with one week 
washing period between them. 
Table 2 shows the pharmacokinetic parameters for ondansetron HCl 
(ONH) in the prepared nanoemulsion in situ gel (NIG), conventional 
prepared in situ gel (IG) and marketed IV injection. From these 
results, it was evident that, the absorption of ondansetron HCl 
(ONH) from the nanoemulsion in situ gel (NIG) reached its peak 
plasma concentration in 2 h, the mean Tmax of marketed Zofran IV 
injection was 0 h (the drug directly inside the blood circulation 
without absorption) while, for the conventionally prepared in situ 
gel (IG), the Tmax was 3 h. Also, it was found that the absolute 
bioavailability (Fabsolute) for nanoemulsion in situ gel (NIG) 
(80.541%) was significantly higher (P<0.001) than that for 
conventional in situ gel (IG) (51.068%). These findings ensure the 
goal of contribution of nanoemulsion technology applied for the situ 
gel preparation in NIG which showed higher and rapid absorption 
than conventional in situ gel(IG) formula, estimated by increasing 
the mean maximum plasma drug concentration (Cmax) and reducing 
the time required to reach maximum plasma drug concentration 
(Tmax), increasing the total amount of ondansetron HCl 
(ONH)present in blood for longer time as indicated by the high value 
of AUC0-α and finally, this in vivo study is inconsistent with the vitro 
release of the drug from both formulas nanoemulsion in situ gel 
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(NIG) and conventional in situ gel (IG)(where the drug gave 100% in 
vitro release after 6 h, while 60% in vitro drug release after 6 h from 
conventional IG), indicating that nanoemulsion technology used in NIG 
improved the bioavailability of the drug (80.541%) through improving 
its release and permeability through nasal cavity[9]. In comparison to 
the reported work for the same drug but is prepared as intranasal 
surface engineered nanostructural lipid carrier showed absolute 
bioavailability (68.24%) which is less than that of nanoemulsion in 
situ gel (NIG) [19]. Also, NIG exceeds the absolute bioavailability of 
oral tablet and oral solution (65% and 71% respectively) [20]. 
The nanoemulsion in situ gel (NIG) formula remains in the nose of the 
experimented rabbit till the end of the study indicating good 
mucoadhesive property of the preparation without drainage or 
detachment during the experimental time. Therefore, this study showed 
that in situ gel nasal preparation prepared by applying nanoemulsion 
technology (NIG) which is liquid at room temperature and upon 
instillation into the nose, it will change to a gel as an acceptable 
alternative dosage form (to IV) with effective, safe, good bioavailability, 
less frequent doses (improves patient compliance) and better result than 
the in situ gel prepared by conventional method (IG). 
 
Table 1: Mean plasma concentration (ng/ml) of ondansetron HCl (ONH)at the time intervals following administration of single dose of the 
prepared nanoemulsion in situ gel (NIG), conventionally prepared in situ gel (IG) and the marketed Zofran®
Time (h) 
 IV injection 
Mean plasma drug concentration (ng/ml) 
IV NIG IG 
0.01 7000±141.80 780.93±48.5 200.91±28.05 
0.25 6850.84±71 1299.5±22.38 381.96±42 
0.5 6482.38±49.99 1644.8±12.34 521.22±57.72 
1 5992.72±92.14 2443.1±49.2 807.27±78 
2 5189.48±71.17 3865.25±63 1827.44±49 
3 4371.01±64.69 3633±53.9 2885.6±49.31 
5.5 3257.87±57.02 2890±82.12 1918.06±42.68 
7.5 2465.86±14.83 2375±93 1489.52±57.98 
10 1700.44±92 1650±129.7 1025.78±49.57 
24 222.5±283 250±51 188.9±49 
n=6 (mean±SD) 
 
Table 2: Pharmacokinetics parameters of a single dose of ondansetron HCl(ONH) from the optimized nanoemulsion in situ gel (NIG), 
optimized in situ gel (IG) formula and the commercial Zofran®
The mean pharmacokinetic parameters 
IV injection 
IV (±SD) NIG (±SD) IG (±SD) P(3)value 
tmax (h) 0±0.0 2±0.0 3±0.0 P<0.001 
Cmax (ng/ml) 7000±141.80 3865.25±57 2885.6±49.31 P<0.001 
AUC1→24 (ng/ml. h) 50816.412±19.9 40698.219±38.0 25250.765±22.9 P<0.001 
AUC1→α(%CV(1) 52428.731 (7.51%) ) (ng/ml. h) 45165.610 (5.59%) 26774.152 (2.17%) P<0.001 
Ke±SEM(2)(h-1 0.138±0.020 ) 0.092±0.041 0.124±0.040 P<0.001 
t1/2 (h) 5.022 7.533 5.589 P<0.001 
%F(absolute) - 86.147 51.068 P<0.001 
%F (relative) (IG/NIG) - - 59.28 - 
n=6 (mean±SD, (1) CV% = Percent coefficient of variation. (2) SEM = Standard error mean, (3) P = Probability value 
 
 
Fig. 3: Mean plasma drug concentration profile versus time obtained during the in vivo pharmacokinetic studies carried out in six rabbits 
receiving single dose of the prepared nanoemulsion in situ g00el (NIG), conventional prepared in situ gel (IG) and marketed (Zofran®) IV 
injection 
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CONCLUSION 
This work describes a fast, sensitive and robust method to quantify 
ondansetron HCl (ONH) in rabbit plasma using HPLC. The described 
method for ONH quantification in rabbit plasma was successfully 
applied in a bioequivalence study of the prepared nanoemulsion in 
situ gel(NIG), conventionally prepared in situ gel(IG) and marketed 
Zofran IV injection using an open, randomized, two-period crossover 
design with a 7 d washout period between doses. Since the prepared 
NIG formula showed high absolute bioavailability suggesting it as a 
good alternative candidate for IV injection that will improve patient 
compliance. The work also proved the role of nano-sized droplets in 
the in situ gel nasal prepared using nanoemulsion technology in 
improving the absorption rate and extent of the drug in comparison 
to conventionally prepared in situ gel preparation. 
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